Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMp
To assess subject-centric real-world evidence of QoL outcomes in subjects enrolled in the global Phase 3 AU-011-301 clinical trial.
| Condition(s) | Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | To assess subject-centric real-world evidence of QoL outcomes in subjects enrolled in the global Phase 3 AU-011-301 clinical trial. |
| Who can participate | Inclusion Criteria: * Have enrolled in the Aura-sponsored clinical trial AU-011-301. * Access to a connected device (i.e., smartphone, laptop, or tablet) Exclusion Criteria: * None |
| Sex | All |
| Lead sponsor | Aura Biosciences |
| Locations | East Melbourne, Victoria, Australia |
| Start date | 2025-11-12 |
| NCT ID | NCT07421739 |
| Official listing | https://clinicaltrials.gov/study/NCT07421739 |